Company
Sinocare, Inc.
Headquarters: Changsha, China
Employees: 3,138
Market Cap
CN¥15.24 Billion
CNY as of Jan. 1, 2025
US$2.09 Billion
Top Competitors by Market Capitalization
Industry: Medical Devices
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Sinocare Inc. engages in the development, manufacture, and marketing of diagnosis rapid testing products primarily in the People's Republic of China. It offers SARS-CoV-2 antibody test strip; Safe-Accu blood glucose monitoring systems; Safe-AQ blood glucose monitoring systems; Gold-Accu blood glucose monitoring systems; Safe-Accu UG blood, glucose, and uric acid monitoring systems; Safe-Accu KG blood, glucose, and ketone monitoring systems; and D Nurse mobile glucose meters. The company provides its products for the patients with chronic diseases and diabetes, as well as for healthcare professionals. It also exports its products to 135 countries. Sinocare Inc. was founded in 2002 and is based in Changsha, the People's Republic of China.
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥4.21 B |
| EBITDA | CN¥441.6 M |
| Gross Profit TTM | CN¥2.19 B |
| Profit Margin | 5.27% |
| Operating Margin | 10.60% |
| Quarterly Revenue Growth | 2.00% |
Stocks & Indices
Sinocare, Inc. has the following listings and related stock indices.
Stock: SZSE: 300298 wb_incandescent